Currently available therapeutic interventions (approved by the Food and Drug Administration (FDA)) against cholestasis include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), a farnesoid X nuclear receptor (FXR) agonist. This evidence concerns the gene NR1H4 and cholestasis.